Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).

Participants with type 2 diabetes preferred the dulaglutide injection device to the semaglutide injection device. If patients prefer a device, they may be more willing to use the medication, which could result in better health outcomes. Furthermore, a shorter training time for injection devices may be helpful in busy clinical practice settings.